Trevena, Inc. (NASDAQ:TRVN – Get Rating) – Research analysts at Oppenheimer lifted their FY2022 EPS estimates for shares of Trevena in a report released on Wednesday, May 11th. Oppenheimer analyst J. Jones now anticipates that the biopharmaceutical company will post earnings of ($0.30) per share for the year, up from their previous forecast of ($0.39). Oppenheimer also issued estimates for Trevena’s Q4 2022 earnings at ($0.07) EPS, FY2023 earnings at ($0.31) EPS, FY2024 earnings at ($0.32) EPS and FY2025 earnings at ($0.31) EPS.
Trevena (NASDAQ:TRVN – Get Rating) last issued its earnings results on Wednesday, May 11th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Trevena had a negative return on equity of 74.90% and a negative net margin of 7,771.74%. During the same period in the prior year, the firm earned ($0.06) earnings per share.
TRVN opened at $0.20 on Monday. The stock has a market cap of $33.60 million, a price-to-earnings ratio of -0.58 and a beta of 2.44. The stock’s 50 day moving average price is $0.39 and its 200-day moving average price is $0.55. Trevena has a one year low of $0.18 and a one year high of $2.20.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in shares of Trevena by 11.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,028,595 shares of the biopharmaceutical company’s stock valued at $3,725,000 after purchasing an additional 306,851 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Trevena in the 3rd quarter worth about $103,000. Barclays PLC acquired a new position in shares of Trevena in the 3rd quarter valued at about $83,000. State Board of Administration of Florida Retirement System acquired a new position in Trevena during the 3rd quarter valued at about $194,000. Finally, Virtu Financial LLC acquired a new position in Trevena during the 4th quarter valued at about $105,000. 21.20% of the stock is owned by hedge funds and other institutional investors.
Trevena Company Profile (Get Rating)
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
- Get a free copy of the StockNews.com research report on Trevena (TRVN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.